Clinical Trial Update: Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update evaluating pharmacokinetics, efficacy, and safety of Encaleret in pediatric participants with autosomal dominant hypocalcemia ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Hypocalcemia Type

Drugs mentioned

• Encaleret (encaleret)

Snippet

Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company | Conditions: Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2, Phase 3 | Status: RECRUITING